Current gold standard therapeutic strategies for T2DM target insulin resistance or β cell
dysfunction as their core mechanisms of action. However, the use of traditional anti-diabetic …

Cardiovascular disease is a leading cause of death in the United States and across the
world, and better therapies are constantly being sought to improve patient outcomes. Recent …

Abstract Glucagon-like peptide 1 (GLP-1)-based therapies reduce hyperglycaemia in type 2
diabetes. Diabetes cardiovascular comorbidity remains prevalent, although current …

Type 2 diabetes mellitus is a well‐established risk factor for cardiovascular disease (CVD).
New therapeutic approaches have been developed recently based on the incretin …

Diabet. Med. 30, 289–299 (2013) Abstract Aims Glucagon‐like peptide‐1 receptor agonists
and inhibitors of dipeptidyl peptidase‐4 that increase glucagon‐like peptide‐1 plasma …

Type 2 diabetes mellitus (T2DM) and obesity are metabolic disorders characterized by
excess cardiovascular risk. Glucagon-like peptide 1 (GLP1) receptor (GLP1R) agonists …

Type 2 diabetes mellitus (T2DM) is a highly prevalent disease that is associated with
development of atherosclerosis and an increase in all-cause mortality. Treatment options for …

Glucagon‐like peptide‐1 (GLP‐1) is an incretin hormone whose glucose‐dependent
insulinotropic actions have been harnessed as a novel therapy for glycaemic control in type …

The discovery that glucagon-like peptide 1 (GLP-1) mediates a significant proportion of the
incretin effect during the postprandial period and the subsequent observation that GLP-1 …

Cardiovascular outcome trials revealed cardiovascular benefits for type 2 diabetes mellitus
patients when treated with long‐acting glucagon‐like peptide‐1 (GLP‐1) receptor agonists …